ImmunityBio, Inc. Common Stock
IBRX
$9.18
-8.20%
ImmunityBio, Inc. is a clinical- and commercial-stage biotechnology company developing next-generation immunotherapies designed to activate both the innate and adaptive immune systems against cancer and infectious disease, built around its proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and a supporting portfolio of adenovirus-vectored vaccines, NK-cell therapies, and immunomodulators. The company is best characterized as a single-asset commercial-stage disruptor in the highly competitive bladder cancer immunotherapy niche, where ANKTIVA is being positioned as a combination partner to BCG rather than a standalone competitor to checkpoint inhibitors. The investor narrative has shifted decisively from speculative platform story to commercial execution story: the FDA's October 2026 expansion of the ANKTIVA label in bladder cancer, the May 2026 acceptance of an expanded-use filing, an NCCN guideline endorsement, EU approval, a first approval in Asia, and an exclusive Japanese BCG supply partnership have collectively re-rated the equity. The debate now centers on whether the roughly 94% year-over-year revenue growth can be sustained as the label broadens, and whether the company can narrow its still-substantial losses before the next financing cycle.…
IBRX
ImmunityBio, Inc. Common Stock
$9.18
Related headlines
Investment Opinion: Should I buy IBRX Today?
Rating: Hold with a speculative buy bias for risk-tolerant investors. The core thesis is that ANKTIVA's commercial rollout is exceeding expectations (94% revenue growth) and recent regulatory expansions (FDA label expansion, EU approval, Japan partnership) provide a multi-year growth runway, but the current valuation already reflects much of this optimism. The analyst consensus is strong buy with an average target of $14.25, implying 55% upside, but the company's $230M quarterly loss and -$365.6M free cash flow highlight the execution risk.
Supporting evidence includes: 1) Revenue growth of 93.9% YoY, with Q2 2026 revenue of $51.24M versus $26.43M a year ago; 2) Gross margin of 99.4%, indicating pricing power and operating leverage; 3) A strong balance sheet with current ratio of 5.10 and $3.16M quarterly interest income; 4) Analyst targets ranging from $12 to $16, all above the current price. However, the PS ratio of 16.1x and EV/Sales of 69.2x are steep relative to the $51M quarterly revenue base, and the company remains unprofitable with a net margin of -310%.
The biggest risks are: 1) Financing risk — the company may need to raise capital within 12-18 months, potentially at dilutive prices; 2) Single-asset concentration — ANKTIVA is the only commercial product, and any setback would be devastating; 3) Competitive pressure in bladder cancer. The rating would upgrade to Buy if the stock pulls back to the $7-8 range (PS ~12x) or if the company demonstrates a clear path to profitability (e.g., operating cash flow breakeven). It would downgrade to Sell if revenue growth decelerates below 50% or if a major clinical/regulatory failure occurs. Valuation verdict: fairly valued to slightly overvalued relative to near-term fundamentals, but justified if growth sustains above 80% for the next two years.
Sign up to view all
IBRX 12-Month Price Forecast
The forward view is balanced: the commercial momentum is real, but the valuation already discounts a successful rollout. The base case (50% probability) sees the stock reaching $11-14 as revenue scales and losses narrow, while the bull case (30%) requires flawless execution across multiple geographies. The bear case (20%) is a real risk given the single-asset profile and financing needs. I would upgrade to bullish if the stock pulls back to $7-8 (PS ~12x) or if the company reports a clear path to operating breakeven. I would downgrade to bearish if revenue growth decelerates below 50% or if a major competitive threat emerges.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on ImmunityBio, Inc. Common Stock's 12-month outlook, with a consensus price target around $14.25 and implied upside of +55.2% versus the current price.
Average Target
$14.25
0 analysts
Implied Upside
+55.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$12 - $16
Analyst target range
Bulls vs Bears: IBRX Investment Factors
The bull case rests on explosive revenue growth (94% YoY), a strong analyst consensus (strong buy, $14.25 average target), and a transformative label expansion that broadens ANKTIVA's addressable market. The bear case highlights the stark lack of profitability ($230M quarterly net loss), extreme valuation multiples (16x PS, 69x EV/Sales), and single-asset concentration risk. Currently, the bull evidence appears stronger given the momentum, analyst support, and recent regulatory wins, but the margin of safety is thin. The single most important tension is whether ANKTIVA revenue can scale fast enough to justify the valuation before the company needs another dilutive financing round — a resolution that will determine whether this is a multi-bagger or a speculative bubble.
Bullish
- Revenue growth accelerating at 94% YoY: Q2 2026 revenue of $51.24M grew 93.9% year-over-year from $26.43M in Q2 2025, and rose sequentially from $44.21M in Q1 2026. This trajectory reflects rapid ANKTIVA adoption following the NCCN guideline endorsement and EU approval, with the FDA's October 2026 label expansion providing a further runway.
- Analyst consensus strong buy with 55% upside: All 4 covering analysts rate the stock a strong buy (recommendation mean 1.25), with an average target price of $14.25 versus the current $9.18 — implying roughly 55% upside. The high target of $16.00 suggests 74% upside, and even the low target of $12.00 is 31% above the current price.
- Massive relative strength versus market: IBRX has returned 262.8% over the past year versus 15.5% for the S&P 500, a relative strength of 247.3 percentage points. Year-to-date the stock is up 354.5% versus 11.9% for the SPY, demonstrating powerful momentum and investor conviction in the commercial story.
- Near-perfect gross margins at 99.4%: Gross margin of 99.4% in Q2 2026 (gross profit $50.94M on $51.24M revenue) reflects the high-value biologics pricing of ANKTIVA and minimal cost of goods. This provides substantial operating leverage as revenue scales, since each incremental dollar of sales drops almost entirely to gross profit.
Bearish
- Deeply unprofitable with $230M quarterly net loss: Q2 2026 net loss was $230.4M on $51.2M revenue, a net margin of -310%, driven by a $168.7M non-operating expense (likely warrant/derivative revaluation) and $112.9M in operating costs. Even excluding the non-cash charge, operating loss was $61.7M, and free cash flow TTM is -$365.6M.
- Extreme valuation multiples versus fundamentals: The stock trades at a PS ratio of 16.1x and EV/Sales of 69.2x, with negative PE and EV/EBITDA. These multiples price in years of hyper-growth, leaving little room for execution missteps. The PEG ratio of 0.15 is based on forward EPS estimates that may be overly optimistic given the current loss run-rate.
- High short interest signals skepticism: Short ratio of 11.29 indicates that it would take over 11 days of average volume to cover all short positions, reflecting significant bearish positioning. This creates potential for violent squeezes but also signals that many investors doubt the sustainability of the rally.
- Single-asset concentration risk: The entire commercial thesis rests on ANKTIVA, a single IL-15 superagonist approved in bladder cancer. Any clinical setback, competitive threat, or manufacturing issue would be catastrophic, as there is no diversified revenue base to cushion the blow.
IBRX Technical Analysis
Beta
0.03
0.03x market volatility
Max Drawdown
-42.3%
Largest decline past year
52-Week Range
$2-$12
Price range past year
Annual Return
+262.8%
Cumulative gain past year
| Period | IBRX Return | S&P 500 |
|---|---|---|
| 1m | +16.1% | +0.2% |
| 3m | +19.5% | +2.9% |
| 6m | +19.2% | +8.4% |
| 1y | +262.8% | +14.9% |
| ytd | +354.5% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IBRX Fundamental Analysis
Quarterly Revenue
$51240000.0B
2026-06
Revenue YoY Growth
+93.9%
YoY Comparison
Gross Margin
99.4%
Latest Quarter
Free Cash Flow
$-365626000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IBRX Overvalued?
PE
-5.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-11.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. The company reported a Q2 2026 net loss of $230.4M on $51.2M revenue, with a net margin of -310%, and free cash flow TTM of -$365.6M. While the current ratio of 5.10 provides near-term liquidity, the cash burn rate implies a need for additional capital within 12-18 months unless revenue accelerates dramatically. The 99.4% gross margin is a strength, but operating expenses (R&D $57.7M, SG&A $50.6M in Q2) remain high, and the company has no approved products beyond ANKTIVA, creating revenue concentration risk. The $168.7M non-operating expense in Q2 (likely derivative revaluation) adds earnings volatility and complicates the path to GAAP profitability.
Market and competitive risks are elevated. The stock trades at a PS ratio of 16.1x and EV/Sales of 69.2x, far above typical biotech peers, pricing in flawless execution. Competition in bladder cancer is intense, with checkpoint inhibitors and other intravesical therapies vying for market share. The beta of 0.03 suggests low correlation with the broader market, but this masks high idiosyncratic volatility — the stock fell 8.2% on the latest trading day. Regulatory risks persist despite recent approvals, and any delay in the EU launch or Japanese partnership could derail growth expectations. Additionally, the high short interest (short ratio 11.29) indicates that many investors are betting against the stock, which could amplify downside moves on negative news.
The worst-case scenario involves a clinical or regulatory setback for ANKTIVA, a failed expansion into new indications, or a financing crunch that forces dilutive equity issuance at depressed prices. In such a scenario, the stock could retrace to its 52-week low of $1.95, representing a 79% decline from the current $9.18. Even a less severe correction to the analyst low target of $12.00 would be upside, but the 52-week low underscores the extreme downside risk. Given the max drawdown of -42.3% over the past year, investors should be prepared for significant volatility. A realistic bear case target of $6.00 (roughly 35% below current) would still be above the 52-week low but would wipe out a third of capital.
FAQ
The most severe risk is financing risk: with a $365.6M annual cash burn and no profitability in sight, the company will likely need to raise capital within 12-18 months, potentially diluting shareholders. Second is single-asset concentration: ANKTIVA is the only commercial product, so any clinical, regulatory, or manufacturing setback would be catastrophic. Third is competitive risk: the bladder cancer market is crowded, and new entrants could erode ANKTIVA's market share. Fourth is valuation risk: the stock's premium multiples make it vulnerable to a sharp correction if growth slows. Finally, the high short interest (short ratio 11.29) indicates that many investors are betting against the stock, which could amplify downside moves.
Our 12-month forecast has three scenarios: bull case (30% probability) targets $14-16, driven by successful EU/Japan launches and FDA label expansion; base case (50% probability) targets $11-14, assuming revenue growth moderates to ~60% and losses narrow; bear case (20% probability) targets $6-8, reflecting competitive pressure or a dilutive financing. The base case is most likely, as it aligns with the analyst average target of $14.25 and assumes continued execution but not perfection. The key assumption is that ANKTIVA revenue reaches ~$280M in 2027, which would still represent impressive growth but at a decelerating rate.
IBRX appears overvalued on traditional metrics: its PS ratio of 16.1x and EV/Sales of 69.2x are far above the biotechnology industry average, and it has negative earnings and cash flow. The PEG ratio of 0.15 looks attractive but is based on forward EPS estimates that may be overly optimistic. Compared to its own history, the stock has rallied 262% in a year and is now near the high end of its range. The market is pricing in years of rapid growth, leaving little margin of safety. A more reasonable valuation would be 8-10x PS, implying a stock price of $5-6, but the growth premium may persist if revenue continues to beat expectations.
From a risk/reward perspective, IBRX offers substantial upside (55% to analyst average target of $14.25) but comes with equally significant risks. The company is growing revenue at 94% YoY and has a strong balance sheet (current ratio 5.10), but it loses $230M per quarter and trades at 16x sales. The biggest downside risk is a financing event or clinical setback that could send the stock back toward its 52-week low of $1.95. For aggressive investors with a high tolerance for volatility and a long time horizon, a small position could be justified as a speculative bet on ANKTIVA's commercial success. However, conservative investors should avoid the stock until there is a clearer path to profitability or a more attractive entry point.
IBRX is more suitable for long-term, risk-tolerant investors than short-term traders. The stock's beta of 0.03 suggests low market correlation, but its idiosyncratic volatility is extreme (max drawdown -42.3% in the past year), making it unsuitable for short-term trading unless one has a high risk appetite and active monitoring. The company pays no dividend and is unlikely to do so for years, so returns depend entirely on capital appreciation. A minimum holding period of 2-3 years is recommended to allow the commercial rollout to mature and for the company to potentially reach profitability. Short-term traders may find opportunities around binary events (FDA decisions, earnings), but these are high-risk gambles.